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STUDY PROTOCOL Open Access
Collaborative treatment of late-life depression in
primary care (GermanIMPACT): study protocol of
a cluster-randomized controlled trial
Iris Wernher1, Frederike Bjerregaard2*, Iris Tinsel3, Christiane Bleich4, Sigrid Boczor5, Thomas Kloppe5, Martin Scherer5,
Martin Härter4, Wilhelm Niebling3, Hans-Helmut König6 and Michael Hüll7
Abstract
Background: Depression is not a normal side effect of aging, however it is one of the most prevalent mental
health issues in later life, imposing a tremendous burden on patients, their families, and the healthcare system.
We describe the experimental implementation of a collaborative, stepped-care model for the treatment of late-life
depression (GermanIMPACT trial) in the German primary care context. GermanIMPACT was developed as an
adaptation of a successful and widely used American model. The aim of the study is to evaluate the model’s
applicability to the German primary care setting and its cost-effectiveness.
Methods/Design: The study will be conducted as a cluster-randomized controlled trial comparing the
development of depressive symptoms in primary care patients who either receive treatment as usual (control arm)
or treatment according to the GermanIMPACT model (intervention arm). In two German cities (Freiburg and
Hamburg), a total of 60 general practice offices will be selected and randomized. Each general practice office will
be asked to enroll five patients into the trial who are 60 years of age or older and who show moderate depressive
symptoms in the scope of a diagnosed depressive episode, recurrent depressive disorder, or dysthymia. General
practices in the control arm will provide treatment as usual; general practices in the intervention arm will work
closely with a specially trained care manager and a supervising mental health specialist. Evidence-based elements
of the treatment plan manual include patient education, identification and integration of positive activities into the
daily routine, relapse prevention, and training of problem-solving techniques as needed. The intervention period per
patient will be one year. Data will be collected at baseline, 6, and 12 months. Primary outcome is the patient-reported
change of depressive symptoms (Patient Health Questionnaire, PHQ-9). Secondary outcomes include measures of
quality of life, anxiety, depression-related behavior, problem-solving skills, resilience, and an overall economic
evaluation of the program.
Discussion: The GermanIMPACT trial will provide evidence about the effectiveness, feasibility, and cost-effectiveness
of collaborative stepped care in treating late-life depression in German primary care. Positive results will be a first step
toward integrating specialized depression care managers into the primary care setting.
Trial registration: German Clinical Trials Register: DRKS00003589 (September 2012).
Keywords: Collaborative care, Late-life depression, Stepped care
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Background
Late-life depression
Depression, including major depression and less severe
forms with clinically relevant depressive symptoms, is
one of the most prevalent mental disorders in older
adults and is considered a serious public health problem.
International studies show that major depression affects
up to 9.3% of individuals aged 75 years or older; less
severe forms occur with a frequency of up to 37.4%
[1,2]. Depression, especially in combination with mor-
bidity, disability, and social disconnectedness, is one of
the key risk factors for suicide in later life [3]. To date,
there are only a few studies on incidence rates of depres-
sion in older adults. Although findings vary considerably
depending on diagnostic criteria and study method, some
results indicate that incident rates in people between 60
and 70 years of age are equal to or lower than those found
in the younger age groups [4]. A recent epidemiological
field study suggested that the incidence and preva-
lence of depression rise again upon reaching the age
of 70, and that cohort effects may further aggravate
this phenomenon [5].
In primary care, the diagnostic situation is complicated
by the fact that late-life depression often manifests as a
mix of somatic conditions and cognitive impairment
[6,7] and often does not present with complaints regard-
ing mood [4]. Hence, it can be assumed that a high
number of older adults suffering from depression remain
undiagnosed [4,8].
Moreover, many people suffering from depression are
poorly educated about the treatability of mood disorders.
Yet another factor to be taken into account is the stigma
associated with mental illness, especially for the older
generation and within the German historical context. As
a result of self-stigmatization, many older adults may
consider depression a sensitive topic and be less likely to
report their symptoms or consult a psychiatrist or psy-
chotherapist [9]. Besides these psychological factors, the
lack of sufficient regional mental health services and
reduced mobility in older age may contribute to the low
number of older patients treated by mental health special-
ists. While older adults suffering from major depression in
Germany tend to see their general practitioner twice as
often as they would without depression, they only have an
average of 0.7 consultations with a psychiatrist or 1.3
consultations with a psychotherapist over a period of 12
months [10]. Given a recommended minimum of four
psychiatric consultations over the course of 12 months for
successful treatment, this means that only 17.5% of older
patients receive a depression-specific intervention.
Collaborative depression care
Cross-national research provides ample evidence for the
advantage of structured collaborative depression care
(CDC) approaches over traditional therapeutic inter-
ventions in primary care [11,12]. Translational research
has encouraged widespread implementation of CDC in
diverse practice settings [13]. In the United States, sev-
eral CDC programs have been evaluated and applied in
practice for more than a decade. Although more research
is needed regarding the cost-effectiveness of the collabora-
tive care approach, recent studies are yielding promising
results [14].
One core feature of CDC in primary care is low-
threshold case management provided by trained nursing
staff or counseling professions, such as social workers
[12,15]. In addition, the involvement of a supervising
mental health specialist (MHS) has proven to be a crucial
and discretely effective element in the interdisciplinary
treatment of depression [13,16-18].
In 2002, Unützer et al. [19] conducted an internationally
recognized and frequently cited randomized controlled
trial on their CDC model (IMPACT: Improving Mood -
Promoting Access to Collaborative Treatment). Since
then, the model has successfully been applied in many
American primary care institutions. The IMPACT treat-
ment plan includes a care manager (CM) and a supervis-
ing MHS. It is designed as a stepped-care model in which
the intervention is tailored to the patients’ individual
needs, allowing for optimal treatment results and minimal
costs. Moreover, IMPACT has proven feasible and effect-
ive not only in the treatment of depression, but of other
psychiatric conditions as well, namely anxiety and panic
disorders [20].
IMPACT: key agents and core elements
The following three professional key agents (providers)
form the IMPACT treatment triad are depicted in
Figure 1.
The first agent in the interdisciplinary triad is the
patient’s primary care provider, typically a general prac-
titioner (GP) in an individual office for the German
context. The GP diagnoses or confirms the diagnosis of
depression and initiates treatment. He or she communi-
cates with the CM on a regular basis in order to ex-
change information about the patient’s progress and to
discuss adequate treatment adaptation as needed.
As central figure in the intervention process, a trained
nurse or social worker in the role of the CM supports
the treatment initiated by the GP by means of proactive
and continuous follow-up with the patient. Intervention
techniques provided by the CM typically include patient
education (regarding symptoms, course of disorder, medi-
cation, side effects and so on), identification and integration
of positive activities into the daily routine, relapse preven-
tion, and training in problem-solving techniques as needed.
These therapeutic elements have been proven to be effect-
ive in the treatment of depression and are recommended
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on high evidence levels by international clinical guide-
lines [21] (based on the procedure used by the Center of
Evidence Based Medicine, all therapeutic elements hold
the highest evidence degree [22]).
The third agent in the IMPACT treatment triad is a
consulting and supervising MHS, that is, a psychiatrist
or psychotherapist. The MHS supervises the interven-
tion through regular meetings with the CM and provides
professional guidance in difficult cases. He or she can
be contacted by the GP regarding medical treatment
options and is available in case of an emergency. In
exceptional cases and after prior consultation with the
CM, the GP can refer a patient directly to the MHS,
for example, if the patient does not respond to the
treatment.
Patient education and counseling provided by the CM
focuses on the modification of cognitive appraisal and
behavior, a powerful tool in the psychotherapeutic treat-
ment of depression. Problem-solving techniques (PST)
as an element of cognitive behavioral therapy are inte-
grated into the treatment plan according to the patient’s
individual symptom remission or lack thereof. The method
has proven successful in numerous depression trials and
can easily be acquired by a wide variety of professionals
working in the healthcare field [23].
Study aim and objectives
In recent years, clinical researchers around the globe
have shown an increased interest in the applicability of
collaborative care models, such as IMPACT, in different
cultural settings and with different patient populations
[15,24]. In Europe, the model has been studied extensively
in the Netherlands and the United Kingdom [25-30]. Until
now, there have been only a few studies in Germany.
Existing studies have not involved an MHS as a core inter-
vention component, for instance, in the form of psychi-
atric supervision [31,32].
The GermanIMPACT trial aims at broadening the
scope of generalizability and the body of evidence for
the adaptability of the IMPACT model to the German
primary care context. Mental health research indicates
that sustainable intervention programs need to be adapted
carefully to existing systems and practices [13]. Thus, one
of the key challenges was to create a concept compatible
with the specific context of primary care in Germany
without affecting the fidelity of the model, especially the
core philosophy and elements.
Positive results in terms of symptom remission in col-
laboratively treated depressive patients will reinforce the
cross-national applicability of the IMPACT core concept.
In addition, such results will underline the impact of
behavioral interventions in depression care and their
successful implementation outside the specialized setting
of high-frequency psychotherapy. The results will serve
the goal of improving the treatment of late-life depres-
sion by paving the way for evidence-based intervention
models in primary care. Proving the efficacy of the col-
laborative approach and its cost-effectiveness will be the
first step towards its implementation into the German
healthcare system.
Figure 1 IMPACT treatment triad (solid line: regular contact; broken line: contact as needed).
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Methods/Design
Setting
GermanIMPACT is a cooperation of the university
medical centers of Freiburg and Hamburg-Eppendorf,
Germany. Both centers serve as study sites, each with
30 participating GPs. The GPs will be recruited through
the centers’ respective general practice departments. The
Freiburg medical center is the coordinating center and is
in charge of the management of data collected in Freiburg.
The Hamburg medical center is responsible for the statis-
tical analysis, assessments related to health economics,
and the management of data collected in Hamburg. At
each site, two CMs with a background in nursing are
appointed and trained. Their offices are based at the
university medical centers. This allows for easy access to
the supervising MHSs who are part of the GermanIM-
PACT team and clinical staff at the medical centers.
Due to the geographic dispersion of German GP
offices and the lack of additional practice space, most
follow-up contacts will be conducted over the telephone.
Research has shown that telephone interventions are a
common and effective tool in depression care [12,17].
Mandatory regular visits requiring traveling on the part
of the patients would most likely be perceived as cum-
bersome and lead to dropouts. Additional face-to-face
sessions will be scheduled only if considered necessary
by the treatment triad.
Sample size
The remission of depressive symptoms as measured by
the Patient Health Questionnaire PHQ-9 at 12 months’
follow-up will be the primary outcome measure of the
study. A randomized controlled trial investigating the ef-
fectiveness of the IMPACT program in the United States
yielded a remission rate of 25.0% in the intervention
group and 8.3% in the control group [19]. Assuming
these remission rates in our trial along with a conven-
tional value for the type I error rate (α = 0.05), a two-
sided test on inequality of proportions requires 85
patients per arm (170 in total) to detect this effect with
a power of 0.8 (type II error rate β = 0.2). Calculations
were done with STATA 12.1 [33]. However, in order to
account for the hierarchical structure of the collected
data due to the cluster-randomized design, it must be
considered that patients treated by the same GP are
likely to be more similar in terms of treatment response
than patients treated by different GPs. Assuming a fixed
number of included GPs (30 per arm, 60 in total) and an
amount of variance in the outcome explained by differ-
ences between physicians rather than between patients
(intraclass correlation coefficient of 10%), the factor of
the necessary increase in sample size (so-called ‘design
effect’) due to the clustered design yields 1.46, increasing
the required sample size to a total of 250 patients. This
is the number needed for an appropriately powered per-
protocol analysis (only completers are analyzed). To
compensate for a conservatively estimated 15% loss to
follow-up [19,31], each participating GP will be instructed
to include 5 patients in the study, amounting to a total of
300 patients allocated to the trial (150 per arm). The pri-
mary analysis will be performed in the intention-to-treat
population, that is, all randomized patients will be inclu-
ded. In the intention-to-treat analysis, the higher number
of patients is likely to be compensated for by a potential
dilution of treatment effects, so that the power will be ap-
proximately the same as described for the per-protocol
analysis.
Recruitment of participants and randomization
Recruitment of GPs
GP offices within a defined radius around the Freiburg
and Hamburg city centers are eligible for enrollment at
cluster level. Participating offices must further be
listed as members of the Association of Statutory Health
Insurance Physicians in the state of Baden-Württemberg
or Hamburg, respectively. Specialized GPs who do not
provide full primary care service, small offices with less
than 400 patients per quarter, GPs offering psychotherapy,
and GPs taking part in another depression trial are ex-
cluded from participation. Both study centers will recruit
GPs stepwise until the targeted number of 30 GPs in each
center is reached (see Figure 2).
Randomization
A cluster-randomized design was chosen over individual
patient randomization in order to avoid intervention
contamination and logistic complications within the GP
offices. Participating GP offices are randomly assigned to
either the intervention or the control arm. To prevent
foreknowledge of treatment assignment, the allocation
of the practices to the study arms will be concealed from
research staff, GPs, and CMs until the intervention
process is activated in the intervention arm: after obtain-
ing written consent from participating GPs, a research as-
sistant generates a pseudonymized code for each practice
and submits this code to an independent statistician at the
Department of Medical Psychology in Hamburg. Partici-
pating practices are then assigned to the intervention or
control group with a 1:1 ratio according to a computer-
generated randomization schedule prepared by the
statistician (STATA 12.1, procedure ralloc). Block rando-
mization is used with three variable block sizes, with
randomization stratified by site. After assignment to the
intervention or control group, the pseudonymized practice
identifiers and the study arm allocation are returned to
the research assistant at the respective study site. This
information is then used to enable intervention activation
at practices in the intervention arm. The randomization
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schedule for the two sites, including the pseudonymized
codes for the practices and their assignment, remains with
the statistician. Study objectives, intervention, and data
assessment pertain to the individual patient level.
Recruitment of patients
Every participating GP is asked to screen his or her
patients according to set inclusion and exclusion criteria
and to include five patients for trial participation in the
GP practice. Patients of the participating GPs who are
60 years of age or older and show moderate depressive
symptoms in the scope of a diagnosed depressive episode,
recurrent depressive disorder, or dysthymia (International
Classification of Diseases, ICD-10, assessment) are eligible
for enrollment at the individual level. Symptom severity is
measured with the nine-item depression scale of the
Patient Health Questionnaire (PHQ-9; inclusion score 10
to 14). Participants must be willing and able to be con-
tacted regularly by the CM via telephone and to partici-
pate in a written survey.
For safety reasons and to avoid data contamination
due to comorbidity effects, patients meeting any of the
following exclusion criteria are excluded from study
participation: alcohol or drug abuse, severe cognitive im-
pairment (e.g., dementia), bipolar disorder, psychotic dis-
order or severe behavioral symptoms, obsessive
compulsive disorder, suicidal ideation and other warning
signs of suicide as well as active non-pharmacological
(or combined) depression treatment by a specialist
(e.g., a psychiatrist or psychotherapist) at time of inclu-
sion. Before GPs apply the PHQ-9 questionnaire, potential
participants receive oral and written information about
the study. If patients agree to participate in the study, both
GP and patient sign the informed consent sheet. Patients,
GPs, and the corresponding local study center receive a
copy of the signed documents. Subsequently, the local
study center will send the baseline questionnaire to the
patient. Completed questionnaires will be reviewed by the
data management team at the local study centers with
regard to exclusion criteria, plausibility of the answers,
and completeness of the data.
Strategy to guarantee the targeted sample size
In case of insufficient patient enrollment by the GPs,
local study centers will recruit additional GPs who will
be randomly allocated to one of the two study arms by
Figure 2 Stepwise recruitment of GPs in both study centers. Abbreviations: GP, General Practitioner; IG, Intervention Group; CG, Control Group.
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the independent statistician (see above). Patients in the
intervention group at each site will receive treatment as
specified in the GermanIMPACT treatment plan man-
ual. Patients in the control group at each site will receive
treatment as usual (as agreed on with their GP without
involvement of a CM and MHS). As the collaborative
care approach was developed to support the treatment
of depression in older adults in general practices, the
comparison to a treatment-as-usual group was chosen
to examine if ancillary care has an additional effect on
symptom remission. This approach is analogous to the
IMPACT study developed in the United States; since
GermanIMPACT is an adaption of the original study, the
same comparative conditions were chosen.
Blinding
Since there is no placebo condition, blinding after
assignment is impossible. However, patients in the inter-
vention and control groups only receive information per-
taining to their respective study arm so that each group
is unaware of the condition of the other group. In both
groups, patient outcomes are collected by the data man-
agement team (assessors) to prevent the involvement of
the CM in patient assessment. The assessors will contact
patients in both study arms repeatedly to ensure a low
rate of missing data. Due to the pseudonymization
process, the statistician will, at all times, be unaware of
the identity of the participating practices. Moreover, the
statistician will analyze the primary and secondary out-
come data without knowledge of the subjects’ allocation
to the study arms. For additional analyses of the treat-
ment process, this kind of blinding is not possible.
Intervention
Warm hand-off
Upon inclusion, patients in the intervention group
schedule an appointment with their GP and their
assigned CM at the GP’s office. The familiarity of the
setting reduces access barriers to mental health services
and increases patient compliance. It is crucial for the
intervention process that the CM be personally intro-
duced to the patient by the GP as a member of the treat-
ment triad; the integration of the CM in the treatment
plan should not be perceived as an external referral.
Care manager-patient contact
In a 60-minute face-to-face session, the CM provides a
short overview of the 12-month treatment period and
introduces the patient to the basic intervention techniques
and the patient workbook. A semi-structured interview
serves to assess the patient’s current health status and be-
havior, symptoms, medication, and psychosocial stressors
and resources; the answers serve as a starting point for the
individual intervention plan. As a first task, the patient is
encouraged to keep an activity journal for the next seven
days.
One week later, the initial session is followed by a 60-
minute telephone session during which behavioral activa-
tion is revisited and patients are sensitized to the positive
relationship between activity and mood improvement.
With the help of the activity journal, a list of pleasant
activities is created from which the patient is encouraged
to choose two and to integrate them into their daily rou-
tine. After this second session, 30-minute telephone ses-
sions are held every other week. Every session consists of
a short symptom assessment via the PHQ-9 and a short
interview including questions about GP visits, medication
effects and adherence, and experiences with the behavioral
activation tasks. Potential barriers for activity planning
and realization are carefully analyzed and new tasks for
the next 14-day period are selected accordingly. Due to
the regular contact between the CM and patient, the CM
can monitor and record deviances from the planned inter-
vention and react instantly to difficulties regarding adher-
ence to the protocol.
The PHQ-9 questionnaire is used throughout the
intervention to assess the current depressive status and
to monitor treatment progress. Research shows that ad-
ministering the PHQ-9 over the phone leads to similar
results as an in-person assessment or self-administration
[34]. Every eight weeks, a treatment evaluation session is
held. Depending on symptom development, the CM can
continue the intervention without changes or offer the
patient different options for treatment adaptation accord-
ing to a stepped-care algorithm. In addition to medication-
related changes (for example, changes in medication
dosage) initiated by the GP and the continuance of
activity planning, the CM can provide training sessions
focused on problem-solving techniques. This is a brief
behavioral intervention intended to reduce depressive
symptoms by teaching patients how to systematically solve
psychosocial problems. For details on this specific inter-
vention, see Hegel et al. [35]. Figure 3 summarizes the
12-month intervention process.
Stepped care
Participating GPs are encouraged to start or continue the
treatment of depression according to clinical guidelines,
including the prescription of antidepressants. They can
contact the supervising MHS at any time for consultation.
The continuous assessment of depressive symptoms
by the CM allows for the close monitoring of treatment
results. CMs and supervising MHSs meet regularly to
discuss every patient’s status. Every eight weeks, the need
for treatment changes is carefully evaluated. The pa-
tient’s PHQ-9 score at baseline serves as the reference
parameter for symptom changes at the eight-week
intervals. Recommendations for treatment adaptation are
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based on a stepped-care algorithm as displayed in Table 1.
The stepped-care approach allows for modifications of the
intervention for each individual participant according to
his or her current health status. The criteria for choosing
the best option within the possibilities of the stepped-care
algorithm are the professional assessment of the GP and
the MHS as well as the personal preference of the patient.
Outcome measures and assessment
Primary outcome
Primary outcome is the change of the PHQ-9 score [36]
as a measure of depressive symptoms over the course of
the study from baseline to the end of intervention. In
line with similar studies [19,25,31], response to treatment
is defined as a symptom reduction of 50% or more, and
Figure 3 Sequence of intervention sessions provided by the care manager (total intervention period = 12 months).
Table 1 GermanIMPACT stepped-care algorithm
Change of current PHQ score compared to baseline Recommended step
Improvement of less than 50% (including no
improvement and worsening of symptoms)
a) Medication-related changes (initiated by the GP) including initiation
if patient is currently without medication, or
b) Training of problem-solving techniques provided by the care manager:
two face-to-face sessions, four telephone sessions (approximately 45 minutes
each); afterwards resumption of telephone sessions at two-week intervals
Improvement of 50% or more No treatment changes
PHQ-9 score <5 (remission) c) Discussion of a relapse prevention and emergency plan
d) Reduction of telephone sessions to four-week intervals; in case of relapse,
resumption of telephone sessions at two-week intervals
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remission is defined as a PHQ-9 score below 5. The PHQ-9
is considered a valid instrument for subgroups of primary
care patients with a high prevalence of major depressive
episodes [37].
Secondary outcomes
Cost-effectiveness measures include the EQ-5D quality
of life questionnaire [38] and a German questionnaire on
resource utilization (Fragebogen zur Inanspruchnahme
medizinischer und nicht-medizinischer Versorgungsleistun-
gen im Alter, FIMA) [39]. As additional measures, a modi-
fied version of the Comorbidity Disease Index (CDI)
[40], the seven-item Generalized Anxiety Disorder Scale
(GAD-7) [41], and a modified version of the Graded
Chronic Pain Scale (CPG) [42] are used. Data on resilience
(13-item Resilience Scale RS-13) [43], depression-related
behavior [44], problem-solving skills (C Bleich and B
Watzke, unpublished manuscript, 2012), and current life
situation (for example, housing and hobbies) are also
collected. In addition, patients in the intervention group
receive a questionnaire on therapy preference (SG Riedel-
Heller, unpublished manuscript, 2012, currently not pub-
licly accessible) and program evaluation (own instrument).
All instruments were chosen according to high standards
of psychometric properties, if available [39,42,43,45].
Assessment
Data are collected at baseline (t0), after 6 months (t1),
and after 12 months (t2 = end of intervention, primary
time of assessment). Patients in the intervention and
control group will receive pseudonymous questionnaires
by mail and are asked to complete and return them to
the GermanIMPACT data management team. Table 2
shows an overview of the outcome measures, instru-
ments, and times of assessment.
To avoid the loss of data at baseline and follow-up as-
sessments, the assessors will contact patients whose
questionnaires are missing by phone in intervals of 10 to
14 days. For patients who choose to discontinue the trial
or deviate from the intervention protocol, a final tele-
phone survey will be conducted. The follow-up calls by
the assessors follow a standard operation procedure
(SOP) that was defined to ensure a structured and sys-
tematic procedure in terms of subsequent collection of
missing data via telephone. This approach is restricted
to items that do not relate to the patient’s psychological
background, with the exception of the PHQ-9 as primary
outcome. If answers to more than one item in the PHQ-
9 are missing, the PHQ-9 will be reassessed completely
by the data management team (in this case, other data re-
garding health status will be declared invalid). Any revision
has to be signed by the assessor with their name and date.
Only completed questionnaires will be passed on to data
entry.
According to the SOP, data will be entered corre-
sponding to the defined coding plan in the EpiData
Entry Client (Version 1.4.2; EpiData Manager Version
1.4.2 for data export) [46]. Instead of running a double
data entry procedure, the entered data will be completely
(100%) checked and, if necessary, corrected by a second
person on the data management team. Data export files
(Stata Version 12.1 and SPSS Statistics Version 21 [33,47])
from both study centers will be centrally collected at the
study center in Hamburg for statistical analysis.
As after assignment the research stuff is not blinded,
no external data monitoring committee is needed, and
data concerning patient safety and treatment efficacy
can be monitored internally. Similarly, auditing of the
trial conduct will be administered by the research staff:
the data management teams in Freiburg and Hamburg
will monitor the completion of the questionnaires, while
the study coordinators will ensure adherence to the
intervention protocol.
Table 2 GermanIMPACT outcome measures, instruments,
and times of assessment
Month 0 6 12*
Time of assessment t0 t1 t2
Primary outcome
Depression (PHQ-9) X X X
Secondary outcomes
Sociodemographic data X partial partial
Comorbidity (CDI, modified**) X – X
Anxiety (GAD-7) X X X
Pain (CPG, modified**) X X X
Resource utilization (FIMA) X X X
Preference-based quality of life
(EQ-5D)
X X X
Resilience (RS-13) X X X
Depression-related behavior
(Ludman et al. [44], modified**)
X X X
Problem-solving skills X X X
Current life situation X X X
Intervention group only
Evaluation of intervention – – X
Therapy preference
questionnaire
X – –
Depression (PHQ-9) - additional
measures
– each
session
– each
session
–
*Primary time of assessment (t2) after intervention.
**Linguistic and culture-specific modifications
Abbreviations: PHQ-9, the Patient Health Questionnaire; CDI, the Comorbidity
Disease Index; GAD-7, the seven-item Generalized Anxiety Disorder Scale; CPG,
the Graded Chronic Pain Scale; FIMA, Fragebogen zur Inanspruchnahme
medizinischer und nicht-medizinischer Versorgungsleistungen im Alter; EQ-5D,
EuroQol Group; RS-13, the 13-item Resilience Scale.
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Statistical analysis
The primary analysis will compare the proportion of pa-
tients remitted of depressive symptoms at the 12-month
follow-up using a mixed-effects logistic regression model
in the intention-to-treat sample (including all random-
ized patients). Treatment condition (intervention versus
control) will be treated as a fixed effect. Baseline severity
of depressive symptoms will be included as a covariate
and variation among patient clusters (treated by the same
GPs) will be modeled through random effects. Further
binary outcomes will be modeled correspondingly. Con-
tinuous outcomes will be analyzed according to the same
scheme, but in linear rather than logistic regression
models. Item-level missing data in psychometrically sound
instruments will be treated in compliance with the corre-
sponding manuals. If no recommendations are available,
the expectation-maximization (EM) algorithm will be used
to impute up to 30% of missing item responses. Unit-level
missing data (patients not providing data for a whole
measurement point due to dropping out of the study, for
example) will be imputed via the EM algorithm using
existing information from the baseline and 6-month
follow-up assessments. Further secondary analyses will in-
clude analyses in the per-protocol (completer) sample to
test the robustness of the primary findings. No interim
analysis is planned. Before the start of the analysis, a
detailed statistical analysis plan (SAP) will be prepared by
the responsible statistician. Intervention-related data are
stored and analyzed separately. All analyses will be com-
puted using Stata 12.1. Figure 4 provides a detailed over-
view of the study design.
Ethical considerations and safety
Good clinical practice
The collaborative care model used in this study has
proven beneficial in numerous trials. The treatment plan
and intervention techniques are compliant with recom-
mendations of current national and international clinical
guidelines. GermanIMPACT follows the regulations of
the Federal and State Data Protection Law and the rec-
ommendations of the Harmonized Tripartite Guideline
for Good Clinical Practice (ICH GCP). All relevant
protocol modifications and amendments will be submitted
to the responsible ethical review boards and will be re-
ported within the scope of the publication of the trial
findings.
Patients with severe depressive symptoms or suicidal
ideation at the time of screening are excluded from
study participation. GPs are encouraged to refer these
patients to an external MHS. Severe depressive symp-
toms or warning signs of suicide that occur during the
intervention can be detected early and be dealt with in a
timely manner. In case of adverse advents, such as the
emergence of warning signs of suicide in the course of
Figure 4 GermanIMPACT study design.
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the intervention, the responsible GP and MHS must be
consulted instantly by the CM and decide on further
action. Different options are possible: 1) GP and MHS
can consult to discuss further action; 2) the MHS can
make a personal appointment with the patient; or 3) the
MHS or GP can initiate further steps, for instance, hospi-
talization. For patients in the control group, the data
management team monitors the development of the
depressive symptoms by screening the incoming question-
naires for suicidal cues. A SOP for screening and step-by-
step instructions are provided, namely, requesting the
patient to see their GP as soon as possible, to make an
appointment with a psychiatrist or psychotherapist, or, in
case of an emergency, to call emergency medical services
directly. The GP and the MHS can then decide about fur-
ther steps for medical care. All adverse events that occur
during the trial will be documented by the CM or, for pa-
tients in the control group, by the data management team.
Study participation does not exclude the option of referral
to an external specialist, although for patients in the inter-
vention group, GPs are encouraged to refer them to the
supervising MHS. Thus, both patient groups have full ac-
cess to all treatment options for depression in the German
healthcare system. As treatment by the GP is maintained
during and after the trial phase, no post-trial care is
intended, and the GP can decide about additional treat-
ment options as needed.
The trial protocol has been granted ethical approval
from the ethical review board of the University of Freiburg
(approval number 150/12) and the ethical review board of
the medical association of Hamburg (approval number
MC-224/12). Written informed consent is mandatory for
each patient for enrollment in the study.
Training of GermanIMPACT care providers
The CMs receive comprehensive training by a psycholo-
gist familiar with the IMPACT concept and intervention
techniques. They are provided with a detailed interven-
tion manual to be used for further study and reference.
Regular meetings with the trainers ensure the continuous
high standard of the intervention. Clinical concerns are
regularly discussed with the supervising MHS. All mem-
bers of the GermanIMPACT study team are educated and
instructed thoroughly in how to deal with emergencies,
such as suicidal ideation.
Prior to participation, GPs are individually contacted by
members of the study team and informed about the aims
of the study and the nature and process of the inter-
vention. Before the inclusion of the first patient, they are
personally introduced to the CM assigned to their office.
Data protection
All patient data collected throughout the study, including
documentation of the intervention sessions, are entered
into the study database using identifiers (pseudonyms)
instead of patient names to grant the highest possible pro-
tection of privacy. The necessary exchange of patient data
between the providers within the treatment triad is clearly
communicated orally, in the patient information and the
informed consent form. Health-related and sociodemo-
graphic data will be stored separately from personal data.
Only authorized staff has access to the data, and data priv-
acy protection according to German Law will be fulfilled.
All institutions cooperating in the study are required to
agree to the data protection procedures. All investigators
will have access to the final trial dataset without any con-
tractual limitations.
Dissemination
The trial is registered in the German Clinical Trials
Registry (DRKS-ID: DRKS0000358). The results of the
trial will be published in international academic journals
and national periodicals for healthcare professionals and
will be disseminated through presentations at scientific
conferences. Participating GPs will receive the publica-
tion of the main analyses and additional information in
lay language to disseminate them to interested patients.
The sponsor will receive a final report including recom-
mendations on development requirements of collaborative
care in late-life depression therapy in primary care - ac-
cording to the results of the trial. There is no restriction
on publication. The trial is conducted according to the
CONSORT statement, and the study protocol conforms
to the Spirit Checklist [48]. The use of professional
writers is not intended. So far, no public access to full
protocol, participant-level dataset, and statistical code
is planned.
Discussion
The IMPACT approach to treat late-life depression
has proven both effective and cost-effective in the
United States for more than a decade. Not surprisingly,
collaborative models are increasingly recognized in in-
ternational research on depression care. The adapted
GermanIMPACT program is tailored to the specific pri-
mary care context in Germany, for instance, with regard
to GP medical practice, office organization, infrastruc-
ture, communication style, and patient characteristics.
By preserving the core principles of the original pro-
gram, we expect that our collaborative intervention will
show effects that are as beneficial as those of its American
counterpart.
In the face of the demographic transition and the high
prevalence rates of clinically relevant depressive symp-
toms in the older age groups, collaborative interventions
for older adults are a forward-looking approach [2].
We expect that older adults can benefit greatly from a
low-threshold intervention like GermanIMPACT that
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supports, but does not replace the usual treatment by
their long-standing family doctor. We hope that the re-
sults from our study will help to identify and under-
stand impeding and facilitating factors to the process
of integrating CMs into a patient’s treatment plan.
Since the notion of collaborative depression care is
fairly new to the German healthcare system, we hope
that the results of the GermanIMPACT study will
yield important insights regarding the applicability of
collaborative models and pave the way for the implemen-
tation of CMs into outpatient depression treatment in
Germany.
Trial status
Enrollment for the trial began in February 2013. Recruit-
ment is still in progress. Data collection is expected to
continue until September 2015.
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